Lassa Fever Market

Key Highlights

• Throughout the forecast period (2024-2034), it is anticipated that the Lassa fever market will maintain a stable Compound Annual Growth Rate (CAGR). This increase in market revenue is primarily driven by advancements in diagnostic techniques, increased awareness of the condition, and a rising number of reported cases.
• The Lassa fever cases are increasing due to various factors including lack of awareness, poor infection control practices, limited healthcare access, and migration or displacement of populations, among others.
• The Lassa fever virus may cause as many as 300,000 human infections and 5000 deaths per year in areas where the disease is endemic.
• The current market for Lassa fever is marked by limited competition, primarily due to the absence of approved treatments and restricted availability of existing options.
• Research on vaccines and the treatment of Lassa fever has been ongoing since 1986. There are currently multiple Lassa therapeutic candidates in the pipeline. Difficulties around the development of vaccines and vaccine research have included access to funding, weak healthcare systems, lack of knowledge about the incidence of the disease (including surveillance or epidemiological data), and the presence of different lineages of the virus in the countries where Lassa fever disease occurs (which might require different kinds of vaccine).
• To drive the Lassa fever market in future years, several companies such as Arisan Therapeutics, Emergent Bio Solutions, Imunon, and others are developing their assets in the mid-late stage of development. With the expected approval of these therapies during the forecast period [2024–2034], the overall therapeutic market of Lassa fever is likely to witness a rise at a significant CAGR.
• Among the emerging therapies, ARN-75039, developed by Arisan Therapeutics, is anticipated to be launched during the forecast period (2024-2034).

DelveInsight’s comprehensive report titled “Lassa Fever — Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of Lassa fever. The report presents historical and projected epidemiological data covering Total Incident Cases of Lassa fever further segmented by Severity. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in Lassa fever. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Lassa Fever Overview

Lassa fever (LF) is an acute viral hemorrhagic illness caused by the Lassa virus, a member of the arenavirus family of viruses. Humans usually become infected with the Lassa virus through exposure to food or household items contaminated with urine or feces of infected Mastomys rats. The disease is endemic in the rodent population in parts of West Africa.

Signs and symptoms of Lassa fever typically occur 1-3 weeks after the patient comes into contact with the virus. For the majority of Lassa fever virus infections (approximately 80%), symptoms are mild and go undiagnosed. Mild symptoms include slight fever, general malaise and weakness, and headache. In 20% of infected individuals, however, the disease may progress to more serious symptoms including hemorrhaging (in gums, eyes, or nose, as examples), respiratory distress, repeated vomiting, facial swelling, pain in the chest, back, and abdomen, and shock. Neurological problems have also been described, including hearing loss, tremors, and encephalitis. Death may occur within two weeks after symptom onset due to multi-organ failure.

Lassa Fever Diagnosis and Treatment Algorithm 

Lassa fever is most often diagnosed using enzyme-linked immunosorbent serologic assays (ELISA), which detect IgM and IgG antibodies as well as Lassa antigen. Reverse transcription-polymerase chain reaction (RT-PCR) can be used in the early stage of the disease. The virus itself may be cultured in 7–10 days, but this procedure should only be done in a high-containment laboratory with good laboratory practices. Immunohistochemistry, performed on formalin-fixed tissue specimens, can be used to make a postmortem diagnosis.

There are no specific guidelines for approaching patients with Lassa Virus, and supportive care remains the primary treatment method.

Ribavirin, an antiviral drug, has been used successfully in Lassa fever patients, particularly when administered early in the course of the illness. Alongside ribavirin treatment, patients should also receive supportive care, including maintenance of appropriate fluid and electrolyte balance, oxygenation, and blood pressure. Additionally, treatment should address any complicating infections. To prevent primary transmission of the Lassa virus from its host to humans, it's crucial to avoid contact with Mastomys rodents, especially in geographic regions where outbreaks occur.

Lassa Fever Epidemiology

The epidemiology section on the Lassa fever market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the incidence of Lassa fever. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

During the Lassa fever analysis, it was found that approximately 80% of people who become infected with the Lassa virus have no symptoms. 1 in 5 infections result in severe disease, where the virus affects several organs such as the liver, spleen, and kidneys. 

It was found that Lassa fever is infrequently encountered in areas where the disease is not endemic, and it is usually seen in persons returning from Africa.

The analysis observed that approximately 232 persons were exposed to a case of Lassa fever imported into Germany.

The epidemiology of Lassa fever is expected to change during the forecast period (2024-2034).

Lassa Fever Market Outlook

The Lassa fever therapeutics market is further expected to increase by the major drivers, such as the rising incident population, technological advancements, and upcoming therapies in the forecast period [2024–2034].

In August 2023, Imunon announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the immunogenicity and efficacy of two IMUNON DNA-based Lassa virus vaccine candidates. Under the three-year agreement, the NIAID will assess the effectiveness of PlaCCine DNA constructs against the Lassa virus in guinea pig and non-human primate disease models, including both prime and prime-boost vaccine strategies.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Lassa fever market in the 7MM is expected to change significantly during the study period 2020–2034.

Lassa Fever Drug Chapters 

Emerging Lassa Fever Drugs

The Lassa fever market is expected to experience gradual changes, mainly due to the expected launch of emerging therapies in this area. Key market players, including Arisan Therapeutics, Emergent Bio Solutions, Imunon, and others, have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.

ARN-75039: Arisan Therapeutics

In collaboration with the Defense Threat Reduction Agency (DTRA), Battelle Memorial, and the National Institute for Allergy and Infectious Disease (NIAID), Arisan Therapeutics has identified and is currently evaluating ARN-75039 in Phase I clinical studies. This initiative aims to provide a potent, convenient, and urgently needed oral broad-spectrum Lassa therapeutic. The company is currently recruiting candidates for the Phase I clinical trial for this drug.

EBS-Lassa: Emergent Bio Solutions

In September 2022, Emergent Bio solutions dosed the first participant in its Phase I study evaluating the safety and immunogenicity of EBS-LASV. This vaccine candidate is a recombinant VSV-vectored Lassa virus vaccine being developed for the prevention of disease caused by Lassa virus infection. Emergent Bio solutions and CEPI (the Coalition for Epidemic Preparedness Innovations) are co-funding this program.

Note: Detailed emerging therapies assessment will be provided in the final report.

Lassa Fever Market Segmentation

DelveInsight’s ‘Lassa fever – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future Lassa fever market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies. 

Lassa Fever Market Size by Countries

The Lassa fever market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2023, the United States held a significant share of the overall 7MM (Seven Major Markets) Lassa fever market, primarily attributed to the country's higher incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Lassa Fever Market Size by Therapies

Lassa Fever Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034. 

Lassa Fever Drugs Uptake

This section focuses on the sales uptake of potential Lassa fever drugs that have recently been launched or are anticipated to be launched in the Lassa fever market between 2020 and 2034. It estimates the market penetration of Lassa fever drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Lassa fever market.

The emerging Lassa fever therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Lassa fever market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on Lassa fever.

Lassa Fever Market Access and Reimbursement

DelveInsight’s ‘Lassa Fever – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of Lassa fever.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments. 

KOL Views

To keep up with current Lassa fever market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the Lassa fever domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Lassa fever market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Lassa fever unmet needs.

Lassa fever: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Travelers Medical Service of Washington, George Washington University School of Medicine, Georgetown University School of Medicine in the US, Robert-Koch-Institute, and Department of Virology, Bernhard-Nocht-Institute of Tropical Medicine in Germany, among others.

“The disease can cause a range of outcomes, including fever, vomiting, and swelling of the face, pain in the chest, back and abdomen, bleeding of various parts of the body including the eyes and nose and death.”

“Because of difficulties in diagnosing Lassa fever, the lack of standardized surveillance assays, and the remote nature of many of the areas in West Africa where outbreaks typically occur, the numbers of reported cases and deaths may be lower than the actual numbers.”

“Lassa Fever is difficult to distinguish from a host of other febrile illnesses, at least during its onset.” 

Note: Detailed assessment of KOL Views will be provided in the full report on Lassa fever.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the Lassa fever Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Lassa Fever Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Lassa fever. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, patent details, and other information for emerging Lassa fever therapies.

Lassa Fever Report Insights

• Lassa fever Patient Population
• Therapeutic Approaches
• Lassa fever Pipeline Analysis
• Lassa fever Market Size and Trends
• Lassa fever Market Opportunities
• Impact of Upcoming Therapies

Lassa Fever Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Lassa fever Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Lassa fever Market
• Lassa fever Drugs Uptake

Lassa Fever Report Assessment

• Lassa Fever Current Treatment Practices
• Unmet Needs
• Lassa Fever Pipeline Product Profiles
• Lassa Fever Market Attractiveness

Key Questions

• How common is Lassa fever?
• What are the key findings of Lassa fever epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for Lassa fever?
• What are the disease risk, burden, and unmet needs of Lassa fever?
• At what CAGR is the Lassa fever market and its epidemiology is expected to grow in the 7MM during the forecast period (2024–2034)?
• How would the unmet needs impact the Lassa fever market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of Lassa fever in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2024–2034)?
• How many companies are currently developing therapies for the treatment of Lassa fever?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Lassa fever Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.